Skip to main content
ADMA BIOLOGICS, INC. logo

ADMA BIOLOGICS, INC. — Investor Relations & Filings

Ticker · ADMA ISIN · US0008991046 US Manufacturing
Open in API
Filings indexed 962 across all filing types
Latest filing 2022-02-11 Major Shareholding Noti…
Country US United States of America
Listing US ADMA

About ADMA BIOLOGICS, INC.

https://www.admabiologics.com/

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company that develops, manufactures, and commercializes specialty plasma-derived biologics. The company's portfolio features FDA-approved immune globulin (Ig) products for the treatment of immune-compromised patients and individuals at risk for certain infections. ADMA Biologics operates a vertically integrated manufacturing process for its specialty biologic products and utilizes a patented immunotechnology platform, which includes a proprietary microneutralization assay to measure neutralizing antibody levels in plasma. The company also offers contract manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2022
Major Shareholding Notification
2022-02-11 English
ADMA BIOLOGICS, INC.
Major Shareholding Notification
2022-02-04 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 19, 2022, reporting preliminary unaudited fourth quarter and full year 2021 revenues and a 2022 business update. It includes a press release as an exhibit. The document is relatively short (3599 characters) and primarily serves as a current report to announce financial results and business updates, typical of an Earnings Release. It is not a full annual or quarterly report, nor a certification or regulatory filing of another type. Therefore, the best classification is Earnings Release (ER).
2022-01-19 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text indicates the filing is about a press release announcing FDA approval for a new plasma collection facility. There are no financial statements or detailed financial data included, and the document is relatively short (3202 characters). It primarily serves as a regulatory announcement of a significant corporate event rather than a financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-01-18 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-12-30 English
8-A12B
Regulatory Filings Classification · 95% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. The text describes the adoption of a Rights Agreement related to preferred stock purchase rights, including detailed terms and conditions. This is a regulatory filing related to securities registration and rights issuance, not a financial report, earnings release, or management discussion. It is not an announcement of a report but a formal registration statement. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length and content support this classification with high confidence.
2021-12-21 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.